Advertisement

A Second Infant Reportedly Cleared of HIV After Early Therapy — Physician’s First Watch

Medical News |
March 7, 2014

A Second Infant Reportedly Cleared of HIV After Early Therapy

By Joe Elia

A California baby is apparently the second case of an infant infected perinatally with HIV and showing no signs of infection after beginning early antiretroviral therapy. Details have been presented at the Conference on Retroviruses and Opportunistic Infections. The presentation also updates the progress of the earlier case from Mississippi.

The California baby was started on a three-drug antiretroviral regimen at 4 hours of age. The viral load was at undetectable levels by 11 days of age. Now 9 months old, the baby remains on antiretroviral maintenance therapy and is seronegative.

The Mississippi baby, now 41 months old, has been off antiretroviral therapy for almost 2 years. The child remains HIV seronegative.

Asked to comment, Paul Sax, author of the NEJM Journal Watch blog "HIV and ID Observations," wrote that the clinical implications of this case — most notably, whether the baby is in fact cured of HIV — remain uncertain since the baby is still on antiretroviral therapy.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement